Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Melanoma 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1EGFR-mutant Non-small Cell Lung Cancer 1Colonic Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 6Carboplatin 6Pemetrexed 5Cisplatin 5pembrolizumab 4Paclitaxel 4Docetaxel 4sargramostim 3Taxes 3Bevacizumab 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2Radiotherapy, Conformal 2Platinum 2Etoposide 2Erlotinib Hydrochloride 2Cetuximab 2vandetanib 1tetrathiomolybdate 1spartalizumab 1sintilimab 1romidepsin 1ribociclib 1nazartinib 1naporafenib 1motexafin gadolinium 1motesanib diphosphate 1methoxyamine 1fludarabine phosphate 1canakinumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma of Lung × naporafenib × Clear all
NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Novartis

Phase 1 Terminated
241 enrolled
DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡